Catalent Inc

BBG005XR47W7

Equity

ISIN null / Valor 23576319

New York Stock Exchange, Inc (2024-12-17)

USD 63.48%

Catalent Inc
UMushroom community rating:

0.00 0 votes No rating yet

NegativeNeutralPositive

About company

Catalent Inc. is a leading global provider of advanced delivery technologies, development, and manufacturing solutions for the pharmaceutical, biotechnology, and consumer health industries. As a Contract Development and Manufacturing Organization (CDMO), Catalent plays a crucial role in the lifecycle of medical and health products by offering a broad range of services. These services include the development of drug formulations, biologic and biosimilar development, clinical trial solutions, and the manufacturing and packaging of drugs in various dosage forms. The company's expertise in improving drug delivery mechanisms and its comprehensive supply chain solutions make it a vital partner for innovators looking to bring superior health products to market. Catalent's commitment to enhancing patient care through its services underscores its position as a key player in the health care sector, aiming to accelerate the availability of medical advancements globally.

Summarized from source with an LLMView SourceSector: Technology

Revenue Growth

In the fourth quarter of fiscal 2024, Catalent Inc. reported net revenue of $1.30 billion, marking a 23% increase as reported, or 24% in constant currency, compared to the same quarter in the previous year. Excluding COVID-related revenue, the net revenue increased by 29% compared to Q4'23. For the entire fiscal year 2024, the company achieved net revenue of $4.38 billion, which represents a 3% increase as reported, or 2% in constant currency, compared to fiscal 2023.

Net Earnings and Loss

Catalent Inc. recorded net earnings of $23 million for the fourth quarter of fiscal 2024, a significant improvement from a net loss of $(110) million in the same quarter of the previous year. However, for the full fiscal year 2024, the company reported a net loss of $(1.04) billion, reflecting challenges faced throughout the year.

Adjusted EBITDA

The fourth quarter of fiscal 2024 saw Catalent Inc.'s Adjusted EBITDA increase by 150% as reported, reaching $305 million, compared to $122 million in Q4'23. For the full fiscal year 2024, Adjusted EBITDA was $703 million, showing a modest increase of 1% as reported, or remaining flat in constant currency, compared to the previous fiscal year.

Segment Performance

In the fourth quarter of fiscal 2024, Catalent Inc.'s Biologics segment reported a 51% increase in net revenue, while the Pharma and Consumer Health segment saw a 7% increase. The Biologics segment's EBITDA margin improved significantly to 22.4%, compared to a negative margin in the previous year, while the Pharma and Consumer Health segment's EBITDA margin increased to 31.1% from 27.4%.

Debt and Leverage

As of June 30, 2024, Catalent Inc. had total debt of $4.91 billion, with net debt amounting to $4.62 billion after accounting for cash and equivalents. The company's net leverage ratio was 6.6x, consistent with the same period in the previous year, and well within the senior secured credit agreement requirement of remaining below 6.5x.

Summarized from source with an LLMView Source

Key figures

53.0%1Y

-49.4%3Y

20.5%5Y

Performance

11.9%1Y

55.1%3Y

46.9%5Y

Volatility